Italy Insulin Drugs and Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The Italy Insulin Drugs and Delivery Devices Market size is estimated at USD 531.86 million in 2024, and is expected to reach USD 572.96 million by 2029, growing at a CAGR of 1.5% during the forecast period (2024-2029).

Between February and March 2021, the Italian Association of Diabetes Doctors (AMD) conducted a survey among its members to assess the impact of the SARS-CoV-2 pandemic on the volume of care provided by diabetes services in Italy, as well as to analyse the measures implemented during the national lockdown. Through planning, urban health initiatives promote healthy lifestyles. Health literacy refers to an individual's ability to comprehend, access, and apply information in ways that promote and maintain good health. Italy has joined the Action Network on Measuring Population and Organizational Health Literacy (M-POHL), which conducted a survey between 2019 and 2021 to establish a baseline level of health literacy that can be used to plan health policy measures to improve health literacy and track the health outcomes of such measures over time.

The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS offers to citizens, with or without partial contributions based on a patient's income. The Insulin pens are free of cost for all diabetic patients in Italy, but they must still adhere to a nominal set of medical assistance guidelines that remain free of charge.

Technological development is gaining momentum in the insulin devices market. Over the years, in fact, several technological innovations have been developed that have led to the creation of new types of devices that are more comfortable for patients compared to the traditional ones. Such advantages have helped the rise in the adoption of these products in the Italian market.

Italy Insulin Drugs And Delivery Devices Market Trends

Growing Diabetes and Obesity Population in Italy

According to the International Diabetes Federation (IDF), diabetes will affect nearly 10% of the global adult population (536.6 million people) by 2021, with 1.2 million children and adolescents (aged 19) who have type 1 diabetes. In Italy, the percentages are lower: 5.6%, according to the National Institute of Statistics (ISTAT), and 4.7%, according to PASSI surveillance data collected among adults aged 18-69. ISTAT and PASSI discovered that prevalence was higher in the south than in the center and north.

The Italian National Healthcare Service (NHS) ensures universal coverage for all citizens. People living with diabetes have access, with no out-of-pocket expenditure, to all the medicines, devices, and medical services they need. Overall, Italy has a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery. The Italian health system is highly decentralized, with most administrative and organizational powers held by the Regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus.

The Insulin Pumps Segment is Expected to Witness Highest Growth Rate Over the Forecast Period

An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.

Insulin Pump held a major market share in the insulin delivery devices market in 2021 and is expected to grow with a CAGR of more than 4.3% during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes (T1DM) people. Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.

Italy Insulin Drugs And Delivery Devices Industry Overview

Italy Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support